Literature DB >> 27893962

Proteopathic Strains and the Heterogeneity of Neurodegenerative Diseases.

Lary C Walker1.   

Abstract

Most age-related neurodegenerative diseases are associated with the misfolding and aberrant accumulation of specific proteins in the nervous system. The proteins self-assemble and spread by a prion-like process of corruptive molecular templating, whereby abnormally folded proteins induce the misfolding and aggregation of like proteins into characteristic lesions. Despite the apparent simplicity of this process at the molecular level, diseases such as Alzheimer's, Parkinson's, Creutzfeldt-Jakob, and others display remarkable phenotypic heterogeneity, both clinically and pathologically. Evidence is growing that this variability is mediated, at least in part, by the acquisition of diverse molecular architectures by the misfolded proteins, variants referred to as proteopathic strains. The structural and functional diversity of the assemblies is influenced by genetic, epigenetic, and local contextual factors. Insights into proteopathic strains gleaned from the classical prion diseases can be profitably incorporated into research on other neurodegenerative diseases. Their potentially wide-ranging influence on disease phenotype also suggests that proteopathic strains should be considered in the design and interpretation of diagnostic and therapeutic approaches to these disorders.

Entities:  

Keywords:  Alzheimer's disease; Aβ; Parkinson's disease; amyloid; prion; synuclein; tau

Mesh:

Substances:

Year:  2016        PMID: 27893962      PMCID: PMC6690197          DOI: 10.1146/annurev-genet-120215-034943

Source DB:  PubMed          Journal:  Annu Rev Genet        ISSN: 0066-4197            Impact factor:   16.830


  25 in total

Review 1.  Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Authors:  Anna Villar-Piqué; Matthias Schmitz; Niccolò Candelise; Salvador Ventura; Franc Llorens; Inga Zerr
Journal:  Mol Neurobiol       Date:  2018-02-10       Impact factor: 5.590

2.  Aβ Plaques.

Authors:  Lary C Walker
Journal:  Free Neuropathol       Date:  2020-10-30

3.  2.7 Å cryo-EM structure of ex vivo RML prion fibrils.

Authors:  Szymon W Manka; Wenjuan Zhang; Adam Wenborn; Jemma Betts; Susan Joiner; Helen R Saibil; John Collinge; Jonathan D F Wadsworth
Journal:  Nat Commun       Date:  2022-07-13       Impact factor: 17.694

Review 4.  Biomolecular Assemblies: Moving from Observation to Predictive Design.

Authors:  Corey J Wilson; Andreas S Bommarius; Julie A Champion; Yury O Chernoff; David G Lynn; Anant K Paravastu; Chen Liang; Ming-Chien Hsieh; Jennifer M Heemstra
Journal:  Chem Rev       Date:  2018-10-03       Impact factor: 60.622

5.  Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease.

Authors:  Jay Rasmussen; Jasmin Mahler; Natalie Beschorner; Stephan A Kaeser; Lisa M Häsler; Frank Baumann; Sofie Nyström; Erik Portelius; Kaj Blennow; Tammaryn Lashley; Nick C Fox; Diego Sepulveda-Falla; Markus Glatzel; Adrian L Oblak; Bernardino Ghetti; K Peter R Nilsson; Per Hammarström; Matthias Staufenbiel; Lary C Walker; Mathias Jucker
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

6.  Sabotage by the brain's supporting cells helps fuel neurodegeneration.

Authors:  Lary C Walker
Journal:  Nature       Date:  2018-05       Impact factor: 49.962

Review 7.  Selective vulnerability in neurodegenerative diseases.

Authors:  Hongjun Fu; John Hardy; Karen E Duff
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

8.  A standard model of Alzheimer's disease?

Authors:  Lary C Walker; David G Lynn; Yury O Chernoff
Journal:  Prion       Date:  2018-10-09       Impact factor: 3.931

Review 9.  Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease.

Authors:  Dan Li; Cong Liu
Journal:  Nat Chem Biol       Date:  2021-01-11       Impact factor: 15.040

Review 10.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.